Engineered dendritic cells from cord blood and adult blood accelerate effector T cell immune reconstitution against HCMV

Molecular Therapy Methods and Clinical Development

Volumn 2, Issue , 2015, Pages 14060-

  Daenthanasanmak, Anusara ^a   Salguero, Gustavo ^a   Sundarasetty, Bala Sai ^a   Waskow, Claudia ^b   Cosgun, Kadriye Nehir ^b   Guzman, Carlos A ^c   Riese, Peggy ^c   Gerasch, Laura ^a   Schneider, Andreas ^a   Ingendoh, Alexandra ^a   Messerle, Martin ^a   Gabaev, Ildar ^a   Woelk, Benno ^a   Ruggiero, Eliana ^d   Schmidt, Manfred ^d   von Kalle, Christof ^d   Figueiredo, Constanca ^a   Eiz Vesper, Britta ^a   von Kaisenberg, Constantin ^a   Ganser, Arnold ^a   Stripecke, Renata ^a   more..

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b CENTER FOR REGENERATIVE THERAPIES DRESDEN   (Germany)

^c Centre for Infection Research   (Germany)

^d GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; CD34 ANTIGEN; CYTOMEGALOVIRUS ANTIGEN PP65; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; LENTIVIRUS VECTOR; CD8 ANTIGEN; DENDRITIC CELL VACCINE; IMMUNOGLOBULIN G; INTEGRASE; T LYMPHOCYTE RECEPTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; EFFECTOR CELL; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; HUMAN CELL; HUMAN CYTOMEGALOVIRUS; HUMAN TISSUE; MOUSE; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PRE T LYMPHOCYTE; PRIORITY JOURNAL; SPLEEN CELL; T LYMPHOCYTE; THYMUS; UMBILICAL CORD BLOOD; VIRUS IMMUNITY; ADULT; ANIMAL MODEL; B LYMPHOCYTE; BLOOD; BONE MARROW; CELL DIFFERENTIATION; CELL ENGINEERING; CELL THERAPY; CYTOMEGALOVIRUS INFECTION; IMMUNITY; IN VITRO STUDY; LYMPH NODE; MEMORY T LYMPHOCYTE; MONOCYTE; NEWBORN; SPLEEN;

EID: 84937679958     PISSN: None     EISSN: 23290501     Source Type: Journal    
DOI: 10.1038/mtm.2014.60     Document Type: Article

References (50)

1. 1 Boeckh, M, Ljungman, P, How we treat cytomegalovirus in hematopoietic cell transplant recipients. Blood 113 (2009), 5711–5719.
2. 2 Schmidt-Hieber, M, Labopin, M, Beelen, D, Volin, L, Ehninger, G, Finke, J, et al. CMV serostatus still has an important prognostic impact in de novo acute leukemia patients after allogeneic stem cell transplantation: a report from the Acute Leukemia Working Party of EBMT. Blood 122 (2013), 3359–3364.
3. 3 Boeckh, M, Nichols, WG, The impact of cytomegalovirus serostatus of donor and recipient before hematopoietic stem cell transplantation in the era of antiviral prophylaxis and preemptive therapy. Blood 103 (2004), 2003–2008.
4. 4 Handgretinger, R, Klingebiel, T, Lang, P, Schumm, M, Neu, S, Geiselhart, A, et al. Megadose transplantation of purified peripheral blood CD34(+) progenitor cells from HLA-mismatched parental donors in children. Bone Marrow Transplant 27 (2001), 777–783.
5. 5 Aversa, F, Tabilio, A, Velardi, A, Cunningham, I, Terenzi, A, Falzetti, F, et al. Treatment of high-risk acute leukemia with T-cell-depleted stem cells from related donors with one fully mismatched HLA haplotype. N Engl J Med 339 (1998), 1186–1193.
6. 6 Douek, DC, Vescio, RA, Betts, MR, Brenchley, JM, Hill, BJ, Zhang, L, et al. Assessment of thymic output in adults after haematopoietic stem-cell transplantation and prediction of T-cell reconstitution. Lancet 355 (2000), 1875–1881.
7. 7 Milano, F, Pergam, SA, Xie, H, Leisenring, WM, Gutman, JA, Riffkin, I, et al. Intensive strategy to prevent CMV disease in seropositive umbilical cord blood transplant recipients. Blood 118 (2011), 5689–5696.
8. 8 McGoldrick, SM, Bleakley, ME, Guerrero, A, Turtle, CJ, Yamamoto, TN, Pereira, SE, et al. Cytomegalovirus-specific T cells are primed early after cord blood transplant but fail to control virus in vivo. Blood 121 (2013), 2796–2803.
9. 9 Steinman, RM, Decisions about dendritic cells: past, present, and future. Annu Rev Immunol 30 (2012), 1–22.
10. 10 Wendland, M, Willenzon, S, Kocks, J, Davalos-Misslitz, AC, Hammerschmidt, SI, Schumann, K, et al. Lymph node T cell homeostasis relies on steady state homing of dendritic cells. Immunity 35 (2011), 945–957.
11. 11 Verdijk, P, Aarntzen, EH, Lesterhuis, WJ, Boullart, AC, Kok, E, van Rossum, MM, et al. Limited amounts of dendritic cells migrate into the T-cell area of lymph nodes but have high immune activating potential in melanoma patients. Clin Cancer Res 15 (2009), 2531–2540.
12. 12 Grigoleit, GU, Kapp, M, Hebart, H, Fick, K, Beck, R, Jahn, G, et al. Dendritic cell vaccination in allogeneic stem cell recipients: induction of human cytomegalovirus (HCMV)-specific cytotoxic T lymphocyte responses even in patients receiving a transplant from an HCMV-seronegative donor. J Infect Dis 196 (2007), 699–704.
13. 13 Daenthanasanmak, A, Salguero, G, Borchers, S, Figueiredo, C, Jacobs, R, Sundarasetty, BS, et al. Integrase-defective lentiviral vectors encoding cytokines induce differentiation of human dendritic cells and stimulate multivalent immune responses in vitro and in vivo. Vaccine 30 (2012), 5118–5131.
14. 14 Pearson, T, Shultz, LD, Miller, D, King, M, Laning, J, Fodor, W, et al. Non-obese diabetic-recombination activating gene-1 (NOD-Rag1 null) interleukin (IL)-2 receptor common gamma chain (IL2r gamma null) null mice: a radioresistant model for human lymphohaematopoietic engraftment. Clin Exp Immunol 154 (2008), 270–284.
15. 15 Marodon, G, Desjardins, D, Mercey, L, Baillou, C, Parent, P, Manuel, M, et al. High diversity of the immune repertoire in humanized NOD.SCID.gamma c-/- mice. Eur J Immunol 39 (2009), 2136–2145.
16. 16 Salguero, G, Daenthanasanmak, A, Münz, C, Raykova, A, Guzmán, CA, Riese, P, et al. Dendritic cell-mediated immune humanization of mice: implications for allogeneic and xenogeneic stem cell transplantation. J Immunol 192 (2014), 4636–4647.
17. 17 Riegler, S, Hebart, H, Einsele, H, Brossart, P, Jahn, G, Sinzger, C, Monocyte-derived dendritic cells are permissive to the complete replicative cycle of human cytomegalovirus. J Gen Virol 81:Pt 2 (2000), 393–399.
18. 18 Sinzger, C, Hahn, G, Digel, M, Katona, R, Sampaio, KL, Messerle, M, et al. Cloning and sequencing of a highly productive, endotheliotropic virus strain derived from human cytomegalovirus TB40/E. J Gen Virol 89:Pt 2 (2008), 359–368.
19. 19 Moutaftsi, M, Mehl, AM, Borysiewicz, LK, Tabi, Z, Human cytomegalovirus inhibits maturation and impairs function of monocyte-derived dendritic cells. Blood 99 (2002), 2913–2921.
20. 20 Riddell, SR, Greenberg, PD, Principles for adoptive T cell therapy of human viral diseases. Annu Rev Immunol 13 (1995), 545–586.
21. 21 Einsele, H, Roosnek, E, Rufer, N, Sinzger, C, Riegler, S, Löffler, J, et al. Infusion of cytomegalovirus (CMV)-specific T cells for the treatment of CMV infection not responding to antiviral chemotherapy. Blood 99 (2002), 3916–3922.
22. 22 Kapp, M, Tan, SM, Einsele, H, Grigoleit, G, Adoptive immunotherapy of HCMV infection. Cytotherapy 9 (2007), 699–711.
23. 23 Hervas-Stubbs, S, Perez-Gracia, JL, Rouzaut, A, Sanmamed, MF, Le Bon, A, Melero, I, Direct effects of type I interferons on cells of the immune system. Clin Cancer Res 17 (2011), 2619–2627.
24. 24 Demeure, CE, Byun, DG, Yang, LP, Vezzio, N, Delespesse, G, CD31 (PECAM-1) is a differentiation antigen lost during human CD4 T-cell maturation into Th1 or Th2 effector cells. Immunology 88 (1996), 110–115.
25. 25 Kohler, S, Thiel, A, Life after the thymus: CD31+ and CD31- human naive CD4+ T-cell subsets. Blood 113 (2009), 769–774.
26. 26 Sung, H, Schleiss, MR, Update on the current status of cytomegalovirus vaccines. Expert Rev Vaccines 9 (2010), 1303–1314.
27. 27 Griffiths, PD, Stanton, A, McCarrell, E, Smith, C, Osman, M, Harber, M, et al. Cytomegalovirus glycoprotein-B vaccine with MF59 adjuvant in transplant recipients: a phase 2 randomised placebo-controlled trial. Lancet 377 (2011), 1256–1263.
28. 28 Kharfan-Dabaja, MA, Boeckh, M, Wilck, MB, Langston, AA, Chu, AH, Wloch, MK, et al. A novel therapeutic cytomegalovirus DNA vaccine in allogeneic haemopoietic stem-cell transplantation: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Infect Dis 12 (2012), 290–299.
29. 29 Lilja, AE, Mason, PW, The next generation recombinant human cytomegalovirus vaccine candidates-beyond gB. Vaccine 30 (2012), 6980–6990.
30. 30 Hanley, PJ, Cruz, CR, Savoldo, B, Leen, AM, Stanojevic, M, Khalil, M, et al. Functionally active virus-specific T cells that target CMV, adenovirus, and EBV can be expanded from naive T-cell populations in cord blood and will target a range of viral epitopes. Blood 114 (2009), 1958–1967.
31. 31 McLaughlin-Taylor, E, Pande, H, Forman, SJ, Tanamachi, B, Li, CR, Zaia, JA, et al. Identification of the major late human cytomegalovirus matrix protein pp65 as a target antigen for CD8+ virus-specific cytotoxic T lymphocytes. J Med Virol 43 (1994), 103–110.
32. 32 Moss, P, Khan, N, CD8(+) T-cell immunity to cytomegalovirus. Hum Immunol 65 (2004), 456–464.
33. 33 Jahn, G, Scholl, BC, Traupe, B, Fleckenstein, B, The two major structural phosphoproteins (pp65 and pp150) of human cytomegalovirus and their antigenic properties. J Gen Virol 68 (Pt 5) (1987), 1327–1337.
34. 34 Varnum, SM, Streblow, DN, Monroe, ME, Smith, P, Auberry, KJ, Pasa-Tolic, L, et al. Identification of proteins in human cytomegalovirus (HCMV) particles: the HCMV proteome. J Virol 78 (2004), 10960–10966.
35. 35 Browne, EP, Shenk, T, Human cytomegalovirus UL83-coded pp65 virion protein inhibits antiviral gene expression in infected cells. Proc Natl Acad Sci USA 100 (2003), 11439–11444.
36. 36 Abate, DA, Watanabe, S, Mocarski, ES, Major human cytomegalovirus structural protein pp65 (ppUL83) prevents interferon response factor 3 activation in the interferon response. J Virol 78 (2004), 10995–11006.
37. 37 Cristea, IM, Moorman, NJ, Terhune, SS, Cuevas, CD, O'Keefe, ES, Rout, MP, et al. Human cytomegalovirus pUL83 stimulates activity of the viral immediate-early promoter through its interaction with the cellular IFI16 protein. J Virol 84 (2010), 7803–7814.
38. 38 Williams, KM, Hakim, FT, Gress, RE, T cell immune reconstitution following lymphodepletion. Semin Immunol 19 (2007), 318–330.
39. 39 McClory, S, Hughes, T, Freud, AG, Briercheck, EL, Martin, C, Trimboli, AJ, et al. Evidence for a stepwise program of extrathymic T cell development within the human tonsil. J Clin Invest 122 (2012), 1403–1415.
40. 40 Lang, J, Kelly, M, Freed, BM, McCarter, MD, Kedl, RM, Torres, RM, et al. Studies of lymphocyte reconstitution in a humanized mouse model reveal a requirement of T cells for human B cell maturation. J Immunol 190 (2013), 2090–2101.
41. 41 Chen, Q, He, F, Kwang, J, Chan, JK, Chen, J, GM-CSF and IL-4 stimulate antibody responses in humanized mice by promoting T, B, and dendritic cell maturation. J Immunol 189 (2012), 5223–5229.
42. 42 Suzuki, M, Takahashi, T, Katano, I, Ito, R, Ito, M, Harigae, H, et al. Induction of human humoral immune responses in a novel HLA-DR-expressing transgenic NOD/Shi-scid/γcnull mouse. Int Immunol 24 (2012), 243–252.
43. 43 Jaiswal, S, Pazoles, P, Woda, M, Shultz, LD, Greiner, DL, Brehm, MA, et al. Enhanced humoral and HLA-A2-restricted dengue virus-specific T-cell responses in humanized BLT NSG mice. Immunology 136 (2012), 334–343.
44. 44 Park, KD, Marti, L, Kurtzberg, J, Szabolcs, P, In vitro priming and expansion of cytomegalovirus-specific Th1 and Tc1 T cells from naive cord blood lymphocytes. Blood 108 (2006), 1770–1773.
45. 45 Hanley, PJ, Lam, S, Shpall, EJ, Bollard, CM, Expanding cytotoxic T lymphocytes from umbilical cord blood that target cytomegalovirus, Epstein-Barr virus, and adenovirus. JoVE, 2012, e3627.
46. 46 Borst, EM, Hahn, G, Koszinowski, UH, Messerle, M, Cloning of the human cytomegalovirus (HCMV) genome as an infectious bacterial artificial chromosome in Escherichia coli: a new approach for construction of HCMV mutants. J Virol 73 (1999), 8320–8329.
47. 47 Hazenberg, MD, Otto, SA, Cohen Stuart, JW, Verschuren, MC, Borleffs, JC, Boucher, CA, et al. Increased cell division but not thymic dysfunction rapidly affects the T-cell receptor excision circle content of the naive T cell population in HIV-1 infection. Nat Med 6 (2000), 1036–1042.
48. 48 Schmidt, M, Schwarzwaelder, K, Bartholomae, C, Zaoui, K, Ball, C, Pilz, I, et al. High-resolution insertion-site analysis by linear amplification-mediated PCR (LAM-PCR). Nat Methods 4 (2007), 1051–1057.
49. 49 Paruzynski, A, Arens, A, Gabriel, R, Bartholomae, CC, Scholz, S, Wang, W, et al. Genome-wide high-throughput integrome analyses by nrLAM-PCR and next-generation sequencing. Nat Protoc 5 (2010), 1379–1395.
50. 50 Bolotin, DA, Shugay, M, Mamedov, IZ, Putintseva, EV, Turchaninova, MA, Zvyagin, IV, et al. MiTCR: software for T-cell receptor sequencing data analysis. Nat Methods 10 (2013), 813–814.